Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial [0.03%]
特氟瑞迪尼/泰普拉西尔联合或不联合贝伐珠单抗和XB2001（抗IL-1α抗体）的I期临床研究：一项单中心试验
Marion Thibaudin,Nicolas Roussot,Chloé Burlot et al.
Marion Thibaudin et al.
In the tumour microenvironment, IL-1α promotes neoangiogenesis, matrix remodelling, tumour proliferation, chemoresistance, and metastases. Highly expressed in human colorectal cancers, IL-1α is associated with poor prognosis. XB2001, a fu...
Tissue-resident immune cells: from defining characteristics to roles in diseases [0.03%]
组织驻留免疫细胞：从定义特征到疾病中的作用
Jia Li,Chu Xiao,Chunxiang Li et al.
Jia Li et al.
Tissue-resident immune cells (TRICs) are a highly heterogeneous and plastic subpopulation of immune cells that reside in lymphoid or peripheral tissues without recirculation. These cells are endowed with notably distinct capabilities, setti...
Real-world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study [0.03%]
阿兹夫定与帕罗维德治疗新冠肺炎住院患者的有效性和安全性：一项多中心回顾性队列研究
Haiyu Wang,Guangying Cui,Ming Cheng et al.
Haiyu Wang et al.
Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,87...
Beyond incretins: targeting neurokinin receptors for obesity treatment [0.03%]
incretin以外的靶点：作用于神经激肽受体的肥胖症治疗药物
Doreen Thor,Simone Prömel
Doreen Thor
Tianzuo Zhan,Johannes Betge,Nadine Schulte et al.
Tianzuo Zhan et al.
Cancers of the digestive system are major contributors to global cancer-associated morbidity and mortality, accounting for 35% of annual cases of cancer deaths. The etiologies, molecular features, and therapeutic management of these cancer ...
Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells [0.03%]
具有新型细胞内模块的嵌合抗原受体改善T细胞的抗肿瘤性能
Pengju Wang,Yiyi Wang,Xiaojuan Zhao et al.
Pengju Wang et al.
The excessive cytokine release and limited persistence represent major challenges for chimeric antigen receptor T (CAR-T) cell therapy in diverse tumors. Conventional CARs employ an intracellular domain (ICD) from the ζ subunit of CD3 as a...
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease [0.03%]
细胞周期调控蛋白激酶与细胞周期调节在生物学和疾病中的作用
Ilenia Pellarin,Alessandra Dall&#x;Acqua,Andrea Favero et al.
Ilenia Pellarin et al.
Cyclin Dependent Kinases (CDKs) are closely connected to the regulation of cell cycle progression, having been first identified as the kinases able to drive cell division. In reality, the human genome contains 20 different CDKs, which can b...
A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 [0.03%]
针对SARS-CoV-2奥密克戎亚变体BA.1、BA.2、BA.2.12.1、BA.4和BA.5的广谱中和抗体
Zhe Chen,Leilei Feng,Lei Wang et al.
Zhe Chen et al.
The global spread of Severe Acute Respiratory Syndrome Coronavirus 2. (SARS-CoV-2) and its variant strains, including Alpha, Beta, Gamma, Delta, and now Omicron, pose a significant challenge. With the constant evolution of the virus, Omicro...
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer [0.03%]
索采利珠单抗联合卡铂和依托泊苷对比安慰剂联合卡铂和依托泊苷治疗广泛期小细胞肺癌的多中心、随机、双盲、Ⅲ期临床研究
Zhiwei Chen,Jianhua Chen,Dingzhi Huang et al.
Zhiwei Chen et al.
This is a randomized, double-blind, placebo-controlled phase 3 clinical trial (ClinicalTrials.gov, NCT04878016) conducted in 54 hospitals in China. Adults who were histologically diagnosed and never treated for extensive-stage small cell lu...
Targeting pathological brain activity-related to neuroinflammation through scRNA-seq for new personalized therapies in Parkinson's disease [0.03%]
通过scRNAseq针对帕金森病相关神经炎症的病理脑活动，寻求新的个性化治疗方案
Daniela Mirzac,Manuel Bange,Sebastian Kunz et al.
Daniela Mirzac et al.